Share
It is okay to talk about money
Understanding treatment costs can help you and your family plan one step at a time. You do not have to work this out alone. You may want to ask: “How much will the treatment cost? How are we going to fund it? Will we be able to afford it? What additional expenses should we plan for?” Your care team can help you find the right people to discuss estimates, payment options and possible support.
Talking about cost is a normal part of planning cancer care. You can ask before your first treatment or at any point after treatment has started. Ideally, speak to the team before a treatment or payment is due. If a bill is already due, or you have missed a visit because of money, you can still ask for help.
A short note to take away from the conversation
You can copy this note onto paper or print it and ask the hospital team to help complete it.
| What we need to know | Our plan |
|---|---|
| Care planned and when it is due | ________________________________ |
| Amount we need to arrange before that visit | ₹ __________ / still to be confirmed |
| Funding approved, and what is still pending | ________________________________ |
| Who will help with the unresolved question | Name and contact: __________________ |
| When we will speak again | Date: __________ Method: __________ |
You can start with just the name of the person who will help and the question you need answered.
You do not need a complete budget before starting this conversation. Tell the team what you would like help with, even if you do not yet know the costs. Ask for help to understand the treatment options, likely costs and support that may be available.
Sometimes a less expensive treatment offers similar benefit; sometimes the differences matter. Your oncologist can explain this for your situation.
Who can help with money matters at the hospital?
Start with your oncology coordinator, nurse or reception. You can say, “We need help with treatment costs. Who should we speak to?” Ask for a name and contact details so that you know where to return with questions. Job titles and services vary between hospitals.
Hospital teams and what they do
| Person or team | How they can help | A question you could ask |
|---|---|---|
| Oncologist and clinical team | Explain the treatment, expected benefit, alternatives, timing and tests. Any treatment change needs clinical advice. | “Is there a less expensive option with similar benefit for me?” |
| Financial counsellor | Help you understand estimates, likely costs you will pay yourself, possible funding routes and available payment arrangements. | “Can you help us work out the total cost and how much we still need to arrange?” |
| Insurance desk or TPA desk | Coordinate cashless requests, documents and insurer queries. A third-party administrator (TPA) helps administer claims for an insurer. | “What has been approved, what is pending and what might I have to pay?” |
| Health-scheme desk | Check government or employer-scheme eligibility, hospital participation, referral requirements and treatment-package authorisation. | “Does my scheme cover this treatment at this hospital, and what approval is needed?” |
| Billing or estimates department | Prepare estimates and itemised bills; explain charges, package inclusions, deposits, adjustments and refunds. | “Can you show me what is included and what could be charged separately?” |
| Cashier or payments team | Accept payments through the hospital’s authorised methods, issue receipts and explain payment or refund procedures. | “Which payment methods can I use, and when will this payment appear on my account?” |
| Medical social worker or patient-welfare team | Assess practical and social needs; help with eligible grants, supporting documents, accommodation, transport and family support. Availability varies. | “Are there funds or practical support that my family could apply for?” |
| Patient relations or grievance team | Help when a billing query or difficulty with hospital services remains unresolved. | “Who can review this issue and give us a written response?” |
Hospital financial counsellors help you understand the costs of care at that hospital and explain estimates and payment arrangements. They do not act as independent financial advisers on how you should fund treatment, borrow money or invest.
The hospital and its insurance desk help prepare and submit paperwork and coordinate queries with your insurer. The insurance company decides whether the claim is covered and how much it will pay, based on your policy terms and its assessment of the claim. The hospital cannot guarantee the outcome.
If you need an explanation or disagree with a decision, you or your caregiver should contact the insurance company directly. The hospital can help by providing medical records and supporting documents. The section on insurance queries and complaints explains the steps you can take.
If there is no financial counsellor or social worker, ask who helps patients with estimates, insurance and funding applications. You can request a private conversation, an explanation in your preferred language, or help with forms if these are difficult to manage.
How can payments be made?
Hospitals may accept UPI, debit or credit cards, bank transfers, cash within applicable limits, or other approved methods. Ask which are accepted, whether transaction limits or charges apply, and whether you need to pay a deposit before a planned visit. Confirm the hospital’s payee details using its official payment counter or verified channel.
Keep a receipt for every payment, linked to the correct patient and hospital number. Ask how deposits are adjusted against the final bill and how refunds are processed. A card payment or an instalment offer may involve borrowing: check the total cost and repayment terms before agreeing.
Your hospital contact sheet
Oncology coordinator: ____________________
Financial counsellor: ____________________
Insurance / TPA desk: ____________________
Health-scheme desk: ____________________
Billing and payments: ____________________
Medical social worker: ____________________
Patient relations: ____________________
Clinical advice / urgent treatment concerns: ____________________
Understand the treatment plan before estimating the cost
The starting point is the care you need. Once the treatment plan is clear, the hospital can prepare a more useful estimate. Ask your oncologist:
- What is the aim: cure, reducing the chance of cancer returning, controlling the cancer, or easing symptoms?
- What treatments are needed, and in what order?
- How many cycles, visits or months are expected? If treatment has no fixed end date, when will we review it?
- Which tests will guide treatment or check whether it is working?
- What are the alternatives, and how do their benefits and side effects compare?
- How soon should treatment start, and which decisions need to be made first?
A cycle is a planned period of treatment and recovery. Its length depends on the medicines used. A price “per cycle” may exclude blood tests, consultations or supportive medicines, so ask what it includes.
For a treatment that continues for many months or years, request a monthly estimate and a longer-term projection, with a review date. It is reasonable for some details to remain uncertain until test results or the response to treatment are known.
If tests are still pending, ask which costs can be estimated now and which need to wait for the results. Before leaving, it is okay to say, “Could you write down the plan and explain that part once more?”
Questions to take to the next appointment
Choose the two or three questions that matter most to you. You can ask the others at another conversation.
- What is the goal and expected benefit of this treatment?
- Is a less expensive, medically reasonable alternative available?
- What is the likely cost of the whole planned course?
- What could change that estimate?
- What will insurance or my scheme pay, and what will I pay?
- Who can help with funding applications and medicine assistance?
- When should we review both the treatment and the financial plan?
Understand the benefit of each treatment option
When treatments have different prices, ask what each is expected to achieve for you. A higher price does not by itself mean a better treatment. Your oncologist can explain what the proposed option adds compared with the best suitable alternative.
- Does it improve the chance of cure or reduce recurrence?
- Does it help people live longer, control the cancer for longer, or relieve symptoms?
- How large is that benefit for people with my type and stage of cancer?
- What are the side effects, hospital visits and effects on daily life?
- How certain is the evidence, and does my tumour need a particular test result to benefit?
- When will we assess whether it is helping, and when would we stop or change it?
An example: understanding benefit in numbers
Ask how many people benefit, as well as the percentage change. Consider a hypothetical example in breast cancer: with the usual treatment, 20 out of 100 people would have the cancer return within five years. Suppose adding Drug A reduces this to 15 out of 100.
That means five fewer recurrences for every 100 people treated over those five years. The absolute reduction is 5 percentage points, from 20% to 15%. The relative reduction is 25%, because five is one quarter of the original 20. Both figures describe the same benefit, but the relative figure alone does not show how many fewer people would have a recurrence.
Drug A and these numbers are made up to explain the calculation. They do not describe a real medicine’s results or estimate your own risk.
Some treatments offer a substantial benefit; others offer a smaller or less certain gain. Your preferences, side effects, quality of life and financial circumstances all belong in the discussion. Your team can help you weigh these factors and choose a medically suitable option that you can manage.
Build a clear picture of the costs
With a treatment plan in mind, you can ask for the costs in manageable parts. Keep the initial investigations, ongoing treatment and possible additional care separate, then look at the likely total.
Separate the initial investigations from ongoing care
Many of the tests to confirm the diagnosis and plan treatment happen at the beginning. It may include consultations, scans, a biopsy, examination of the tissue and tests that help select treatment. Some patients also need a specialist review of existing biopsy material, molecular or genetic tests on the tumour, or both.
These are different from the recurring costs of treatment. However, investigations are not always a one-time expense: a repeat biopsy, a new treatment-planning test or reassessment may be needed later.
| Part of care | Examples to ask about |
|---|---|
| Diagnosis and treatment planning | Consultations, biopsy, pathology review, scans, relevant molecular tests and fitness assessments. |
| Cancer treatment | Medicines, surgery, anaesthesia, radiotherapy planning and sessions, day-unit charges, hospital stay and procedures. |
| Care during treatment | Blood tests, response assessments, anti-sickness medicines, infection treatment, transfusions and other prescribed support. |
| Possible extra care | Unplanned admission, management of side effects, additional procedures or a change of treatment. |
| Recovery and longer-term care | Ongoing medicines, follow-up, physiotherapy, rehabilitation, nutrition support and home care when needed. |
Ask for a useful written estimate
Request separate written estimates for the planned investigations and treatment. For treatment, ask for both the cost of each episode and the likely cost of the planned course. A written estimate is a planning document, not necessarily a fixed-price agreement.
It should identify the treatment, expected number of visits or cycles, medicine costs, hospital charges, included tests, exclusions and likely amount payable by you. Ask whether the figures assume a particular room category, medicine brand or assistance programme. An assistance discount should only be counted once eligibility and supply arrangements are confirmed.
A change in the brand of a medicine between treatment cycles may change the cost of that cycle, even when the prescribed medicine and dose remain the same. Before each cycle, ask whether the same brand is planned. If a different brand is proposed, ask the treating team why it is changing and the pharmacy or billing team how this will affect the price. Ask for any price difference to be explained before treatment and reflected in the updated estimate.
Ask for the estimate’s date, how long prices remain valid, and who will update it. Costs can rise if extra care or different medicines are needed. They can fall if the plan becomes shorter or less intensive. A change does not automatically mean something has gone wrong, but you should be told what changed and why.
Review the estimate when the plan changes, before a major procedure, and at agreed intervals during prolonged treatment. Ask what allowance to make for possible additional costs in your circumstances, rather than relying on a standard percentage.
The total cost and the money needed now are different
Alongside the likely full-course cost, ask the team to mark what you need to pay before each planned visit, what will be paid directly by insurance or a scheme, and what you would have to pay first and claim back later.
Keep unconfirmed costs and pending funding visible in the plan. You can ask the team to help fill these gaps and agree a date to review them.
Your cost and funding worksheet
Period covered: ____________________ Estimate reviewed on: ____________________
Choose a period, such as the planned course or the coming month. Use costs before insurance payments, with any confirmed medicine discount already applied. Include each expense and each source of money only once.
| Expense | Amount (₹) | Due date or frequency |
|---|---|---|
| Initial investigations and second opinion | ||
| Planned treatment and procedures | ||
| Tests and supportive medicines during treatment | ||
| Travel, accommodation and meals away | ||
| Home care, rehabilitation and follow-up | ||
| Health insurance premiums due during this period | ||
| Agreed allowance for possible additional costs | ||
| A. Total expected expenses |
| Resource | Amount (₹) | When available / restrictions |
|---|---|---|
| Income you can allocate to care costs after any time off work | ||
| Savings allocated to this period | ||
| Approved insurance or scheme payment for these expenses | ||
| Confirmed grants, assistance and contributions | ||
| B. Resources included in this plan | ||
| Amount still to arrange: A minus B, if positive |
Check the timing as well as the total. A reimbursement arriving later cannot pay today’s deposit. Restricted grants can only pay eligible expenses. Do not count free medicine both as a reduced expense and as cash received. Because income above is already reduced for time off, do not add the same lost wages again as an expense.
Mark income that is uncertain. Leave unapproved insurance, grants and crowdfunding out of the resources total until confirmed. Then check the due dates separately: money expected later may not meet a payment needed now.
Plan for additional costs associated with treatment
Planning for treatment also means accounting for related expenses beyond the hospital bill.
Include travel, accommodation, meals away from home, parking, childcare, care for other dependants and a companion’s expenses. Repeated short visits can add up. Second opinions may involve consultation fees, review of scans or biopsy slides, courier charges and travel. Ask what records are needed before arranging another appointment.
Ask whether appointments can be coordinated, and whether any follow-up consultations or tests can safely take place closer to home. Keep the treating team involved so that results reach the right person and care stays coordinated.
Work and loss of income
If you feel well enough and want to keep working, discuss flexible hours, working from home, lighter duties, part-time work or a gradual return. If you run a business, temporary delegation may help. The right arrangement depends on your health, job and treatment. You should not feel pressured to work when you are unwell.
Before resigning or changing your employment arrangements, ask Human Resources personnel what will happen to salary, leave, benefits and insurance for you and your dependants. Employer insurance cover may end or change when employment changes. Check the position in writing, including any option to continue or move the insurance cover and the deadline for doing so.
Caregivers can lose income too. A shared care rota, where practical, may reduce the pressure on one person. Allow for changes in both the patient’s and caregiver’s income when planning how to pay for treatment.
Ask about practical support
A social worker may know of suitable help with accommodation, meals or travel. For families of children with cancer, some charities provide these services alongside treatment support. Availability, referral arrangements and eligibility differ. Confirm a place before making travel plans, especially if you are travelling a long distance.
Understanding health insurance during cancer treatment
Take your policy details and treatment estimate to the hospital insurance desk. Ask them to help you find answers to three questions: Is this treatment covered? What might we have to pay? What approval is needed before treatment?
Ask the desk or insurer to help you obtain the policy schedule, full wording, Customer Information Sheet (the policy summary), and any changes or optional benefits. For employer insurance, request the current group-policy benefits. The cover depends on your exact policy and treatment.
Cashless treatment and reimbursement
Cashless means the insurer pays the hospital directly for the approved amount. You may still have to pay a co-payment, excluded items or charges above a limit.
Reimbursement means you pay first and submit a claim with the required records. The insurer then assesses what is payable. You will need to arrange the money for the initial payment, even when the treatment is covered.
Refusal of cashless authorisation does not always mean the treatment is excluded. The insurer may need more information, or the cashless arrangement may not apply. Ask for the reason in writing, whether further documents could resolve it, and whether reimbursement can be considered. Reimbursement is still subject to the policy; it is not guaranteed.
If the answer is unclear or a claim is rejected, there is a step-by-step route for asking for a review below.
Explore the topics below and discuss any relevant questions with your insurance desk.
The words that affect what you pay
| Term | What it means for your planning |
|---|---|
| Sum insured | The cover available under the policy, subject to its conditions. Ask for the remaining usable amount, not only the original headline figure. |
| Family floater | A shared pool of cover for the named family members. Another member’s claim may reduce what is available for your treatment. |
| Co-payment | The percentage of a claim eligible under the policy (an admissible claim) that you must pay. For example, 10% of ₹2,00,000 is ₹20,000, before other applicable deductions. |
| Deductible | An amount that must be met before the relevant cover pays. Check whether it applies to each claim or to eligible claims added together over a policy year. |
| Sub-limit | A separate cap on a treatment, expense or benefit, even when the overall sum insured is higher. |
| Room entitlement | The permitted room category or daily limit. Choosing a higher category can, under some policies, reduce payment for associated charges as well as the room itself. |
| Non-payable items | Expenses excluded by the policy. Ask for an itemised explanation; some consumables may be covered only under a particular benefit or add-on. |
Definitions and their application must be checked in your own policy. Two plans from the same insurer can have different limits.
Outpatient, day-care and inpatient treatment
Outpatient care usually includes consultations, tests and medicines without admission. Day-care treatment is an eligible procedure or treatment carried out without an overnight stay. Inpatient care involves hospital admission as defined by the policy.
Many hospital-expense policies have limited or no routine outpatient cover. An infusion may qualify for day-care cover, while tablets taken at home may need a specific benefit. Oral chemotherapy can have particular policy provisions, so do not assume that all tablets are excluded—or that every cancer tablet is covered.
Pre-hospitalisation and post-hospitalisation benefits may pay for eligible expenses linked to an admissible hospital claim within specified time windows. They do not make every outpatient expense payable. Ask about the number of days, the link to the admission, claim deadlines and required documents.
Admission should be based on medical need. Do not arrange an unnecessary admission simply to try to obtain insurance payment.
What about immunotherapy and other newer treatments?
Ask for written confirmation using the exact medicine or procedure, diagnosis, proposed setting and estimated cost. The phrase “modern treatments covered” is not enough: limits can vary between policy variants.
| Treatment | What to clarify |
|---|---|
| Immunotherapy or targeted therapy | Exact drug, accepted indication, infusion or oral use, treatment setting, separate limits and authorisation for repeat cycles. |
| Hormone treatment | Tablets versus injections, outpatient cover and the cost of treatment continuing for years. |
| Bone-marrow or stem-cell transplantation | Patient and donor testing, cell collection, admission, donor-related exclusions, complications and follow-up. |
| Proton therapy or stereotactic radiotherapy, including CyberKnife | Exact technique, medical justification, covered package, hospital eligibility and any technology-specific limit. |
| Robotic surgery | Procedure and technique, surgeon and equipment charges, package inclusions and sub-limits. |
A treatment’s medical suitability and its insurance coverage are separate questions. An authorisation is also not a promise that every final bill item will be paid.
Second opinions, treatment abroad and clinical trials
These are worth checking separately with your insurer. A second-opinion benefit, overseas treatment cover and clinical-trial cover can have different conditions.
Will my health insurance pay for a second opinion?
Some policies arrange a second opinion through a specified service. This may differ from reimbursing a consultation you book yourself. Before paying, ask:
- Does my insurance cover a second opinion for my cancer, in India or from an overseas specialist?
- Must the insurer arrange it? Is it a review of records, an online consultation or an in-person visit?
- Are there limits on the number of opinions or the amount paid? Are pathology and scan reviews included?
Obtain written confirmation of the benefit and process.
Will my health insurance pay for cancer treatment abroad?
Check that your policy covers planned cancer treatment outside India. Cover for emergencies while travelling does not automatically include travelling abroad for treatment.
- Which countries, hospitals and treatments are eligible, and is approval needed before travel?
- What overseas limit, co-payment, deductible or waiting period applies? Is payment cashless or by reimbursement?
- Are outpatient medicines, tests, complications and follow-up covered?
- Are travel, visas, accommodation and a companion’s expenses included, or must we budget for them separately?
Send the proposed hospital’s treatment plan and estimate to the insurer. Ask for a written decision before booking or paying. A large sum insured alone does not confirm overseas cover.
Can I join a clinical trial, and what will my insurance cover?
Your oncologist and the trial team assess whether a study is suitable and whether you meet its entry requirements. Insurance approval does not establish eligibility for a trial.
Ask your insurer whether joining the proposed trial, in India or abroad, affects cover for routine cancer care, tests or complications. Check exclusions for experimental or unproven treatments.
Ask the trial coordinator for a written breakdown of what the study sponsor pays, what may be claimed from insurance and what you would pay. Separate the study medicine and research-only tests from usual care. Also ask about travel, accommodation, care for treatment-related injuries or complications, and costs after the trial ends. Do not assume that every expense is covered because a study medicine is supplied.
Your hospital insurance desk and trial coordinator can help you put these questions to the right people. Discuss the timing with your oncologist so that enquiries do not lead to an unsafe treatment delay.
Base insurance, top-up and super top-up
A base policy provides cover according to its own limits. A top-up or super top-up adds a separate layer above a stated deductible. It has its own eligibility rules, exclusions and waiting periods.
A conventional per-claim top-up assesses the deductible against an individual claim or defined illness episode. An aggregate super top-up adds eligible expenses over the policy year. Product names are not enough: read how the deductible is actually calculated.
Ask whether the deductible can be met by your base insurer, employer cover or your own payments, and which expenses count. If you have more than one policy, ask the insurers how to coordinate claims. Hospital-expense insurance does not allow recovery of more than the eligible expense.
Restoration and “unlimited restoration”
Restoration replenishes cover under specified conditions. It does not necessarily increase the amount payable for a single claim or immediately fund an ongoing admission.
Ask when it activates, whether it applies to the same person and illness, whether it covers only later claims, and whether a single-claim cap remains. “Unlimited restoration” may describe how often cover is replenished; it does not remove all limits. With repeated chemotherapy visits, ask how the insurer groups the claims.
Renewal dates and long treatment courses
Record the policy-year dates, premium due date and remaining cover. Check how annual benefits reset and how claims spanning a renewal date are allocated. Renewal is different from restoration within the same policy year.
Use these dates to plan payments and applications, not to delay or bring forward treatment solely for insurance reasons. Keep renewal premiums in the budget. Do not assume that a grace period provides uninterrupted cover in every situation.
Before changing insurer, increasing cover or leaving employer insurance, get written advice on continuity, waiting periods, exclusions and acceptance. A newly purchased policy or increased sum insured should not be assumed to cover an already diagnosed cancer immediately.
Check existing critical-illness policies too
You may already have a separate critical-illness policy or a rider attached to another policy. Some pay a lump sum if the diagnosis meets their definition. That can help with expenses beyond hospital bills. Check the precise cancer definition, exclusions, waiting and survival periods, and claim deadline. These benefits differ from reimbursement insurance and do not apply automatically to every diagnosis.
Your insurance summary
- Policy name and number; insurer and TPA contacts.
- Policy-year dates, renewal premium and due date.
- Individual or family cover; current remaining sum insured.
- Co-payment, deductible, room entitlement and relevant sub-limits.
- Exact cancer medicines and procedures confirmed in writing.
- Outpatient, day-care and pre/post-hospitalisation benefits.
- Second-opinion benefit and the required booking route.
- Planned overseas treatment: covered countries, costs and prior approval.
- If considering a clinical trial: written cost responsibilities from the trial team and insurer.
- Restoration conditions and treatment of repeated cycles.
- Base and top-up claim coordination.
- Authorisation numbers, expiry dates and pending queries.
- Reimbursement deadlines and documents required.
Where can financial help come from?
Insurance is one possible source of funding. It is also worth checking employer benefits, government schemes, relief funds and charitable help. You can explore several routes at the same time. Tell each organisation about other cover or assistance, because some schemes cannot be combined and the same hospital expense must not be reimbursed twice.
Start with your employer
If you or a family member has an employer, ask Human Resources personnel about benefits beyond health insurance: medical reimbursement, staff welfare funds, additional discretionary cover, paid leave or other support. Government employees, pensioners and eligible dependants may have scheme entitlements that work differently from private insurance. Ask what is available, which documents are required and whether approval is needed before treatment.
Government schemes and relief funds
The following are starting points for enquiries. The hospital’s health-scheme desk or medical social worker can help you check the route that fits your circumstances.
| Route | Who should enquire and what to check |
|---|---|
| Central Government Health Scheme (CGHS) Ex-Servicemen Contributory Health Scheme (ECHS) Arogya Bhagya Yojane (ABY) Employees’ State Insurance (ESI) | Check whether you or your dependants have an entitlement through employment, retirement or service. ABY operates under the Karnataka Police Health Welfare Trust; ask your department or the scheme desk about eligibility for you and your family. For each scheme, confirm referrals, participating hospitals, medicine supply, treatment authorisation and reimbursement. Rules differ between schemes. |
| Ayushman Bharat PM-JAY | Check household eligibility, enrolment, the hospital’s participation and the exact cancer-treatment package. A card does not mean every medicine or procedure is covered. Ask the scheme desk before incurring planned expenses. |
| Ayushman Vay Vandana for people aged 70 and above | The PM-JAY extension covers this age group irrespective of income, subject to enrolment and scheme rules. People already using CGHS, ECHS or Ayushman CAPF need to consider the required choice of scheme. Confirm the implications before switching. |
| Ayushman Bharat–Arogya Karnataka | Karnataka residents can ask about their beneficiary category, available package, participating hospital and current referral or authorisation requirements. Do not assume rules are identical for every beneficiary or procedure. |
| Karnataka Chief Minister’s Relief Fund | Medical assistance is subject to eligibility and approval. Check current income or ration-card requirements, residence documents, a recent estimate, and restrictions involving insurance or other assistance. Ask the fund office to confirm any eligibility exception or repeat application for your circumstances. |
| Prime Minister’s National Relief Fund (PMNRF) | May provide partial assistance for eligible medical treatment. The official guidance describes treatment at government or PMNRF-empanelled private hospitals, with a medical certificate, hospital estimate and family-income evidence. Approval is not automatic. |
| Health Minister’s Cancer Patient Fund under Rashtriya Arogya Nidhi | A route for eligible low-income patients through designated cancer centres and government hospitals. Ask the treating hospital to check eligibility and help submit the application. The Government’s August 2025 explanation describes assistance up to ₹15 lakh; this is a ceiling, not an assured award. |
Other states may have their own health schemes or Chief Minister’s relief funds. Check the relevant government website. Relief funds are different from insurance: they may provide only part of the cost and can have restrictions on when you apply. Ask whether an application must be approved before treatment or payment.
Charitable funding and practical help
Hospital welfare funds and cancer charities may support eligible patients. The Indian Cancer Society’s Cancer Cure Fund, for example, has financial and clinical eligibility criteria and works through empanelled hospitals. Its Bangalore chapter’s assistance programme accepts applications through hospitals with a formal agreement. These are enquiry routes, not promises of funding.
For childhood cancer, St. Judes India describes accommodation, food supplies and transport support for families staying at its centres. Ask the social worker which suitable services are available locally.
Documents for funding enquiries
Requirements vary. Keep organised copies of the diagnosis and treatment summary, prescription, recent written estimate, bills and receipts, insurance decisions, relevant identity and residence documents, income or ration-card evidence, and bank details when required by the official application. Share sensitive documents only through the appropriate verified route.
| Organisation or scheme | Application date and reference | Next action, person helping and follow-up date | Decision and amount confirmed |
|---|---|---|---|
Crowdfunding
Crowdfunding means asking many people to contribute towards treatment. Indian examples include ImpactGuru, Milaap and Ketto. These examples are not rankings or endorsements. The amount raised can vary. Include donations in your funding plan once they are confirmed and available to use.
Before starting, ask for the complete charges and terms in writing. “Zero platform fee” may still leave payment-processing, transfer, optional promotion or other charges. Check who receives the money, verification requirements, withdrawal timing, and what happens if treatment changes or funds remain unused.
Use a realistic, dated treatment estimate. Include relevant travel, living and recovery expenses transparently rather than understating the need. Obtain the patient’s agreement before publishing their story or photographs. Share only the information needed; redact identity numbers, account details and unrelated medical records.
Can costs be reduced safely?
Once you know the likely costs and available funding, ask whether any expenses can be reduced safely. The aim is to preserve effective treatment and necessary monitoring while avoiding costs that do not add value to your care.
Generics and biosimilars
A generic medicine contains the same active ingredient as its reference medicine. Approved generics must meet the applicable requirements for quality and equivalence. They often cost less because development costs and competition differ from those of the original product. A lower price alone does not mean a medicine is weaker.
A biosimilar is a highly similar version of a biological medicine, which is made using living systems. Unlike a simple chemical medicine, a biological product cannot be copied identically. A properly assessed biosimilar must demonstrate the required similarity, including no clinically meaningful differences in safety and effectiveness from its reference medicine.
Useful questions are: “Is there an appropriate generic or biosimilar for my prescribed medicine? Would you recommend it for me? What would the full-course saving be?” Discuss a change before buying. Correct storage, transport, strength and formulation still matter.
More about medicine approval and the evidence
India’s central medicines regulator is the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General (India), or DCGI. Approval applies to a specific product in a particular country or region. A medicine approved in India by DCGI is not automatically approved by the US Food and Drug Administration (FDA) or authorised in the European Union following European Medicines Agency (EMA) assessment.
Ask your oncologist and pharmacist about the exact product’s Indian approval, evidence, manufacturer, appropriate use and reliable supply. CDSCO publishes guidance on similar biological medicines, also called biosimilars.
Official resource: CDSCO guidance and notices on biological medicines, including the Biosimilar Guideline 2016.
Studies compare a particular biosimilar with the original biological medicine to assess how closely they match in quality, safety and how well they work. The results support the biosimilar that was studied; they do not automatically establish the same evidence for another manufacturer’s product. Ask your oncologist about the evidence and approval for the exact biosimilar being offered to you.
Medicine-assistance programmes
Some manufacturers offer assistance for eligible patients prescribed particular medicines, including some expensive immunotherapies and targeted treatments. Support may reduce the amount a patient pays, but the rules, duration and availability vary. A programme mentioned online may not be open to new patients or may operate only in another country.
Ask the oncology team to help check the official Indian route. Confirm eligibility, what you must pay, when assistance starts, how repeat supplies are arranged and what happens if treatment changes. Compare costs after confirmed assistance, rather than relying on a headline discount.
Medicine-assistance directory: programmes and official contacts in India
If an expensive medicine has been prescribed, your oncology team can help check whether an official assistance programme is available in India. Keep the medicine’s exact name handy and ask which company or programme to contact.
Ask what you would pay, what the programme would provide and how long support would last. Obtain the current eligibility and enrolment terms before counting the support in your budget. A listed programme may not be accepting new patients, and support may cover only some doses.
Some examples below come from company information; others are named in a Ministry of Finance notification dated 1 February 2025. That notification records programmes at that time and does not establish current eligibility. The directory is not a complete list of medicines or programmes.
Lilly and Astellas are included as enquiry routes; their current Indian financial-assistance terms need confirmation. The entries help with access enquiries and are not treatment recommendations.
| Company and programme | Medicines and support to ask about | Official information and contact |
|---|---|---|
| Astellas — Indian oncology access enquiry | Ask about support for the exact Astellas medicine prescribed to you. Current Indian medicine-specific financial-assistance terms could not be verified from public official sources; confirm availability, eligibility and costs with the Indian team. | Astellas official directory — select India. The Indian company’s general contact is +91 22 6157 6000; ask for the oncology patient-access team. This is an enquiry route, not confirmation of funding. |
| AstraZeneca — AZCares patient-support programmes | Ask about AZCares support for osimertinib (Tagrisso), durvalumab (Imfinzi) and trastuzumab deruxtecan (Enhertu). AZCares has separate portal routes for these medicines. Other documented assistance examples include acalabrutinib, olaparib and fulvestrant. Confirm the current eligibility, amount you would pay and duration of support for the exact medicine prescribed. | AstraZeneca India contacts and the AZCares app information. Medicine portals: Tagrisso, Imfinzi and Enhertu. Ask your oncology team to help confirm the appropriate enrolment route and current programme terms. |
| Bristol Myers Squibb (BMS) — SAMBHAV and AARAMBH | SAMBHAV for nivolumab (Opdyta); AARAMBH for luspatercept (Rojuzda). The Indian programme information specifies prescribed Indian approved uses and absence of full reimbursement. Luspatercept treats anaemia in particular blood disorders; it is not a general anticancer treatment. | BMS India programme information; discuss eligibility with your treating clinician. |
| GSK — Phoenix | Dostarlimab (Jemperli) and niraparib (Zejula). GSK announced Phoenix alongside these medicines in India in August 2025. Ask what assistance is currently offered and who can apply. | GSK India contacts and official Phoenix announcement. Ask to be directed to the oncology patient-support team. |
| Johnson & Johnson (J&J) | Amivantamab, teclistamab, daratumumab and ibrutinib — Johnson & Johnson PAP. These are examples in the dated government record. | J&J Innovative Medicine contacts; use the India route. |
| Lilly — Indian patient-support enquiry | Abemaciclib and ramucirumab — ask whether assistance is available for the medicine prescribed to you. Current Indian financial-assistance terms for these medicines could not be verified from public official sources; confirm the programme, eligibility and support directly. | Lilly India patient enquiries: 1800 123 0021. Also see Lilly India contacts. This is an enquiry route, not confirmation that financial assistance will be available. |
| Merck Specialties (Merck India) | Cetuximab — Rainbow; avelumab — My Bavencio Assist; tepotinib — My Tepmetko Patient Access. These are examples in the dated government record. | Merck India healthcare enquiries. Merck India is a different company from MSD; use the contact for your prescribed medicine. |
| MSD | Pembrolizumab — Key-PAP 1.0 / KIRAN, as named in the dated government record. | MSD India; ask your oncology team to confirm the applicable programme. |
| Novartis — UMAANG | Ribociclib and dabrafenib are examples in the dated government record. | Novartis India medical-information service accepts patient-support-programme enquiries. |
| Pfizer — Patient Access Programmes | Pfizer’s December 2022 announcement describes an Indian enrolment route requiring a valid prescription and eligibility documents. Confirm the current route and whether your prescribed medicine is supported. | Pfizer India access information. |
| Roche — Blue Tree | Roche India describes support for people with cancer and other conditions. Ask about your exact prescribed medicine and the assistance currently available. | Blue Tree information. The published oncology contact is 1800-266-3366. |
| Servier — Servier CARE | Servier CARE describes medicine, financial and diagnostic support for eligible patients. Medicines to ask about include Onivyde (pegylated liposomal irinotecan), Tibsovo (ivosidenib) and Voranigo (vorasidenib), listed in Servier’s Indian oncology range. Their listing does not establish assistance eligibility for each medicine. | Servier CARE information and Servier India contacts. Ask which medicine and diagnostic costs the programme may cover. |
| Takeda | Brentuximab vedotin — Takeda PAP, as named in the dated government record. | Takeda India; ask your clinician for the current oncology access route. |
Questions to ask before enrolling
- Is the programme currently accepting patients for my prescribed medicine and condition?
- Does my insurance, employer reimbursement or other funding affect eligibility?
- What must I pay, and what will the programme supply?
- Is approval needed before I buy the medicine? Can any earlier purchase qualify?
- How long does support last, and are there renewal or response-assessment requirements?
- How are medicine supplies delivered and stored, and who should I contact if a supply is delayed?
- What happens if my dose changes, treatment is interrupted or the programme changes?
Keep the approval and terms. Ask who will handle your records and which documents are necessary. Do not assume that a US or European assistance website applies to patients in India. If your medicine or manufacturer is absent from this directory, your oncology team can still enquire through the manufacturer’s official Indian contact.
Other questions that may help
- Is there an established, less expensive treatment with a similar expected benefit?
- Can existing scans or biopsy material be reviewed before tests are repeated?
- Can appointments be coordinated to reduce travel?
- Are there suitable government, charitable or other care arrangements we could explore? What would eligibility, waiting time, treatment availability and continuity involve?
- Could the team review non-essential supplements or products we are buying?
Generics, biosimilars and assistance schemes can make some treatments more affordable in India. However, costs differ greatly between cancers and treatment plans. An individual estimate is more useful than a general comparison of prices between countries.
If cost is making it difficult to follow the treatment plan
Tell the team if you have already missed medicines, tests or visits because of cost. Explain what happened so that they can advise you on a safe plan from here.
Do not stretch tablets, skip doses, take less medicine, miss necessary tests or delay visits to make treatment last longer. Changing treatment this way may reduce its benefit or make it unsafe. Tell the team if cost is making the prescribed plan difficult. They may be able to find a safer alternative.
A dose reduction or treatment pause recommended by your oncologist for side effects or other medical reasons is different from reducing treatment yourself. The right dose and schedule depend on the medicine and your circumstances. Never split or crush cancer tablets unless the team confirms it is appropriate.
When you need more help with costs
If there is still a gap between the cost and the funds available, ask the team to help you review the options. This may be before your first treatment, after the first treatment or later in the course. Ideally, explain the concern before a treatment or payment is due, so there is time to explore options. You can still ask for help if a payment is already due or a visit has been missed.
- Explain the immediate problem. Give the amount, due date and what funding is confirmed or pending.
- Review the estimate and bill. Ask the financial counsellor or billing team to explain unexpected charges and correct any errors.
- Check the available cover. Ask about outstanding authorisation, reimbursement, restoration, other policies and scheme benefits.
- Review support routes. Ask the social worker about suitable grants, practical assistance and medicine programmes.
- Discuss a medically safe plan. Your oncologist can explain alternatives and the consequences of any proposed delay, pause, change or stopping decision.
If care needs to move to another service, ask for a coordinated handover of reports, treatment doses and dates, response assessments and the next planned step. For new or severe symptoms, contact the clinical team promptly rather than waiting for a funding application to finish.
If an insurance claim is rejected or only partly paid
Ask for the written decision, the exact policy clause and an itemised explanation of deductions. Check whether the issue concerns cashless authorisation, missing information, eligibility or a final claim decision. Ask the oncology team for clinical clarification where needed.
- Ask the hospital insurance desk to help check the reason and gather any missing documents.
- If the matter is unresolved, complain in writing to the insurer’s grievance redressal officer. This is the person or team that handles formal complaints. Keep claim numbers, copies and dates.
- You can use IRDAI’s Bima Bharosa to register and track a grievance.
- If eligible, you can approach the Insurance Ombudsman after first complaining to the insurer. This independent complaint service is free and has time and monetary limits. Bima Bharosa is not a compulsory step before every Ombudsman complaint.
An appeal may resolve a mistake or missing-information problem, but it cannot be assumed to succeed. Discuss how to maintain appropriate care while the matter is reviewed.
If you are considering a loan
A loan can make funds available when treatment is needed, but repayments continue even if income falls or treatment takes longer than expected. A hospital-linked finance provider is still a lender; hospital involvement does not make the loan interest-free or suitable for everyone.
Before agreeing, identify the actual bank or finance company. Ask for the Key Facts Statement, the annual percentage rate (APR), all fees, the repayment schedule and the total amount repayable. APR brings interest and relevant charges together to help you compare borrowing costs. Check late-payment charges, any insurance bundled with the loan, early-repayment terms and whether an asset is used as security.
Ask: “Could we still meet these repayments if earnings were lower for six months?” Compare borrowing with confirmed assistance, savings and other realistic options. An independent financial adviser may help with a large commitment.
Support for you and your family
Planning treatment costs can feel easier when the practical work is shared and everyone understands the patient’s wishes. If money discussions feel difficult, you can ask the care team for a private conversation about what is manageable and what matters most to you.
Treatment costs can affect daily life and emotional wellbeing, even when you have insurance. Support with the paperwork, practical arrangements and your concerns can be part of the care you ask for.
If you are the patient
You can choose how much paperwork to manage yourself and who, if anyone, helps you. Agree what that person may discuss on your behalf, and how you want to stay involved in decisions. You can ask for explanations again or for a short written plan.
If you are helping someone with cancer
You do not have to take on every task. With the patient’s agreement, one person could keep receipts, another follow up an application, and another help with travel. If you are the only caregiver, tell the hospital team and ask which tasks they can help with. If you are arranging your own care without a caregiver, you can ask for that help too.
Keep a brief shared note of what has been agreed, who will follow up and by when. Set aside short times to review costs, leaving room for conversations and time together that are about everyday life.
If relatives disagree, ask the oncologist to explain the likely benefits and side effects of the options. Keep the patient’s wishes at the centre and agree on a plan that is medically appropriate and practical for the people involved.
If financial worry is affecting sleep, relationships or your ability to make decisions, ask about counselling or social-work support. You can seek this support while practical funding questions are being worked through.
Plan beyond the current treatment
Looking ahead can help you spread costs and avoid having to make every decision at short notice. Ask which parts of care are likely to continue and when the plan should be reviewed.
The final chemotherapy visit may not be the end of treatment-related costs. Some people need hormone treatment or other medicines for years. Others need rehabilitation, physiotherapy, speech or swallowing therapy, stoma supplies, prostheses, psychological support or help at home.
Ask which of these needs apply to your situation and which are only possibilities. That helps you plan for relevant care without assuming you will need every service listed.
Ask for a follow-up plan that explains which visits and investigations are needed and how often. Tests should follow your clinical needs; there is no single schedule of scans that suits every cancer.
Include transport, insurance renewal, treatment of lasting side effects and return-to-work support in the longer-term budget. A gradual return, workplace adjustments or learning new skills may involve time and expense.
Supportive and palliative care can help with symptoms, daily functioning and family concerns alongside cancer treatment. It should be offered according to need, not presented simply as a cheaper substitute. Ask what services are available and how they are funded.
The worksheets alongside the relevant sections can help you put the information together. Use the ones that are helpful to you and complete them at your own pace.
Leave with a plan you can take one step at a time
You may not have every answer yet. A useful first conversation can still leave you knowing what care is planned, what you need to arrange before it, and who will help with anything unresolved.
Keep the short conversation note with your treatment papers. Return to the estimate when treatment, work or insurance changes, or whenever the plan feels difficult to manage.
Your wishes, the treatment’s likely benefit and what you can manage all belong in these decisions. You can ask questions again, involve someone you trust and seek help with the practical work.
Frequently asked questions
How can I find out what my treatment will cost?
Ask for a written estimate based on your diagnosis and treatment plan, covering both the full planned course and the amount needed before each visit. Check which medicines, tests, hospital charges and follow-up costs are included, what could be extra and what insurance or confirmed assistance may pay. The cost-estimate checklist and worksheet can help you put the figures together.
Who can help us understand the costs and make a funding plan?
Ask your oncology coordinator, nurse or reception for the hospital’s financial counsellor or the person who helps with treatment costs. They can explain estimates and payment arrangements and direct you to the insurance desk, scheme desk or social worker. Ask for one named contact who can help you follow up. Your oncologist can discuss medically suitable treatment options.
What might I still need to pay with cashless insurance?
The insurer pays the hospital directly for the approved amount. Your share may include a co-payment, excluded items or charges above policy limits. Ask the insurance desk for a written breakdown of what is approved, what remains uncertain and what you may need to pay before each planned treatment.
How do I check whether my particular treatment is covered?
Give the insurer the exact medicine or procedure, diagnosis, treatment setting and estimate. Ask for written confirmation of cover, any limits and whether approval is needed again for later cycles. Check tablets taken at home, injections, tests and follow-up separately; the rules may differ. The insurance section explains the questions to ask.
What can I do if cashless approval is refused or a claim is only partly paid?
Ask the insurer for the reason in writing and an itemised explanation of any deductions. The hospital insurance desk can help gather missing records. A refusal of cashless approval may still allow a reimbursement claim, depending on the policy and the reason for refusal. If the decision remains unclear or disputed, use the insurance query and complaint steps. Discuss how to continue appropriate care while the issue is reviewed.
What funding can we explore if we do not have private health insurance?
Ask the hospital’s scheme desk or social worker about employer benefits, government schemes, relief funds, charitable help and medicine-assistance programmes that may fit your circumstances. Take a recent treatment estimate and ask which one or two routes to try first. Some applications need approval before treatment or payment, so ask early. The funding section lists official starting points.
Could a less expensive medicine be suitable for me?
Ask your oncologist whether an appropriate generic or biosimilar is available for the prescribed treatment, and what the saving would be over the full course. A lower price alone does not mean lower effectiveness; the exact product’s approval, evidence and suitability matter. Agree any change with the team and confirm supply and storage arrangements before buying.
How can I find out whether a medicine-assistance programme will help?
Use the medicine-assistance directory with your oncology team to find the official Indian contact for your prescribed medicine. Confirm whether the programme is accepting patients, who is eligible, what you would pay and how long support lasts. Keep the terms in writing. Assistance may cover only some doses or part of the medicine cost, so include it in your plan once it is confirmed.
Why might the bill change from one treatment cycle to the next?
The medicine brand, dose, tests or additional care may change. Even with the same prescribed medicine and dose, a different brand may affect the price. Before each cycle, ask whether the same brand will be used and, if anything has changed, why and how it affects the estimate. Ask the billing team to explain any unexpected difference.
What if we cannot arrange the money before the next treatment?
Tell the oncology team as soon as you can, ideally before treatment is due. Explain the amount needed, the date and what funding is confirmed or pending; you can still ask for help if the figures are incomplete. Ask the team to review the costs, funding options and possible alternative treatment plans. Keep treatment decisions with your oncologist rather than changing doses or postponing care yourself. The steps for getting more help with costs can guide the conversation.
Can we get help with travel or accommodation for treatment?
Ask the social worker or patient-welfare team about suitable local services or charities, and whether appointments can be coordinated to reduce repeat travel. Availability and eligibility vary. Confirm accommodation and any other agreed support before making travel plans, especially if you are travelling a long distance.
Which costs should we plan for after the main treatment ends?
Ask for an individual follow-up plan, including any ongoing medicines, tests, rehabilitation, care for lasting side effects or help at home. Check how often these are needed and what insurance may cover. You will not necessarily need every service listed in this guide; your team can help you plan for the care relevant to you.
Sources and further reading
Sources checked on 16 October 2026. Scientific explanations draw on peer-reviewed research and recognised oncology and regulatory resources. Insurance, funding and programme details use the responsible organisation’s own material. Policies and eligibility can change; confirm the terms that apply to you.
Insurer documents are included to substantiate explanations of policy conditions. They are not recommendations to buy those products.
- Prinja S, Dixit J, Gupta N, et al. Financial toxicity of cancer treatment in India: towards closing the cancer care gap. Frontiers in Public Health. 2023;11:1065737.
Original peer-reviewed multicentre study; financial burden, medical and non-medical costs.
- National Cancer Institute. Financial Toxicity (Financial Distress) and Cancer Treatment — Patient Version.
Evidence summary; financial strain, work and caregiver effects. US insurance provisions were not applied to India.
- US Food and Drug Administration. Generic Drug Facts.
Regulatory explanation of generics; does not establish FDA approval of any Indian brand.
- US Food and Drug Administration. Biosimilars Basics for Patients.
Regulatory explanation of biosimilarity; product-specific approvals remain separate.
- IRDAI. Annual Report 2024–25, health-insurance regulatory developments, printed pages 99–101.
Primary regulator report, hosted by the Life Insurance Council; includes modern-treatment provisions.
- HDFC ERGO. my:Optima Secure policy wording, UIN HDFHLIP26058V082526.
Primary policy example, especially automatic restoration, section B.2.6. Not an insurer recommendation or a universal rule.
- HDFC ERGO. my:health Medisure Super Top Up Insurance policy wording.
Primary policy example for annual aggregate deductible; individual terms govern.
- Niva Bupa. ReAssure 3.0 product and variant information.
Primary insurer information demonstrating variation in room and modern-treatment limits. Not a product recommendation.
- HDFC ERGO. Critical Illness Insurance Policy FAQs.
Primary insurer explanation of fixed benefits and eligibility conditions; no universal waiting or survival period asserted.
- Council for Insurance Ombudsmen. Complaint eligibility and process.
Official grievance route; check current jurisdiction, time limits and monetary limits.
- IRDAI. Bima Bharosa.
Official insurance grievance portal.
- Prime Minister’s Office. Frequently Asked Questions, PMNRF medical assistance.
Official medical-assistance route, hospital requirements and documents.
- Government of Karnataka. Chief Minister’s Relief Fund application instructions and FAQs.
Read with https://cmrf.karnataka.gov.in/intranet/FAQ.aspx. Eligibility exceptions and repeat assistance require confirmation.
- Ministry of Health and Family Welfare. Steps taken to assist cancer patients under Rashtriya Arogya Nidhi. 8 August 2025.
Official explanation of the cancer fund, eligible patients, treatment settings and application routes.
- Ministry of Health and Family Welfare. Ayushman Vay Vandana eligibility and enrolment. 9 December 2024.
Official age-70 extension and interaction with existing schemes; enrolment and package checks remain necessary.
- Government of Karnataka, Bengaluru Urban District. Ayushman Bharat–Arogya Karnataka.
Official state scheme entry point; no uniform referral or coverage amount asserted.
- Ex-Servicemen Contributory Health Scheme. Official beneficiary information.
Official scheme, beneficiary, claim and empanelment routes.
- Central Government Health Scheme. Official portal.
Official scheme entry point. Confirm operational instructions through the beneficiary’s scheme office.
- Indian Cancer Society. Cancer Cure Fund.
Charity’s own eligibility and empanelled-hospital requirements.
- Indian Cancer Society, Bangalore. Financial assistance.
Charity’s own requirements; applications through hospitals with an agreement.
- St. Jude India ChildCare Centres. Approach and facilities.
Charity’s description of accommodation, cooking facilities, rations and hospital transport for resident families.
- Milaap. Crowdfunding pricing.
Platform’s own charges information; no promised fundraising outcome.
- ImpactGuru. Pricing.
Platform’s own information; plan-specific fees and current written terms need confirmation.
- Ketto. Terms of use.
Platform’s own terms, including verification and disbursement conditions.
- Reserve Bank of India. Key Facts Statement for Loans & Advances. RBI/2024-25/18, 15 April 2024.
Primary RBI circular; full text cross-checked in the RBI document reproduced by FIDC: https://www.fidcindia.org.in/wp-content/uploads/2019/06/RBI-KFS-FOR-LOANS-15-04-24.pdf.
- Ministry of Finance. Notification No. 09/2025-Customs, 1 February 2025.
Dated official medicine–assistance programme listing; not proof of current enrolment or individual eligibility.
- Roche India. The Blue Tree Program.
Company-confirmed India programme and official oncology enquiry route.
- Bristol Myers Squibb India. BMS Mumbai patient support programmes.
Company-confirmed SAMBHAV and AARAMBH, medicines and eligibility qualifications.
- Pfizer India. Pfizer launches PAP India, 16 December 2022.
Dated company confirmation of an Indian access route; current enrolment must be checked.
- Novartis India. Medical Information.
Official route expressly accepting patient-support-programme questions.
- AstraZeneca India. Contact us.
Official company enquiry route. See references 47–48 for AZCares and its Tagrisso, Imfinzi and Enhertu portals, and reference 26 for the other dated programme examples.
- MSD India. Official company information.
Company contact route only; programme evidence is the dated government notification.
- Johnson & Johnson Innovative Medicine. APAC contact information.
Select the India medical-information route; programme evidence is the dated government notification.
- Merck India. Contact details.
Official healthcare enquiry route; distinct from MSD.
- Takeda India. Official company website.
Company enquiry route; brentuximab programme evidence is the dated government notification.
- Tata Memorial Centre, MPMMCC. Medical Social Works.
Primary service description used to verify the social-worker role, not to recommend a treatment establishment.
- CDSCO. Biologicals guidance and notices.
Official Indian regulatory source, including the Biosimilar Guideline 2016. Draft revisions are not treated as final standards. Guidance listing checked on 18 October 2026.
- HDFC ERGO. my:Optima Secure prospectus, UIN HDFHLIP26058V082526, claims procedure.
Primary policy example expressly distinguishing cashless refusal from a later reimbursement claim.
- Care Health Insurance. Difference between top-up and super top-up insurance.
Primary insurer explanation of per-claim versus aggregate deductibles; product wording overrides a generic label.
- HDFC ERGO. Health Suraksha Top Up Pro policy wording.
Primary policy example for definitions, linked hospitalisation benefits and renewal conditions; not a plan recommendation.
- Employees’ State Insurance Corporation. Benefits and contributory conditions.
Official benefits reference; eligibility and referral advice should come from the scheme office.
- European Medicines Agency. Biosimilar medicines: marketing authorisation.
Independent regulatory cross-check of similarity, safety and efficacy requirements.
- National Cancer Institute. Palliative Care in Cancer.
Independent check that palliative care can accompany anticancer treatment; US funding rules were not imported.
- ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer. ESMO Open. 2024;9:102992.
Peer-reviewed expert consensus, doi:10.1016/j.esmoop.2024.102992; early assessment and management of financial distress. Abstract and indexed consensus text reviewed.
- Rugo HS, Barve A, Waller CF, et al. Trastuzumab biosimilar randomised clinical trial. JAMA. 2017;317:37–47.
Original comparative clinical evidence, doi:10.1001/jama.2016.18305. Product-specific evidence, not proof for all biosimilars.
- Karnataka State Police. Arogya Bhagya Yojane.
Official scheme overview, cross-checked with the scheme administrator’s ABY information. Identifies the Karnataka Police Health Welfare Trust and police-personnel/family context. Current eligibility and authorisation must be confirmed; historical contribution amounts and hospital counts are not reproduced.
- AstraZeneca. AZCares: company-published Indian programme description.
The developer’s description on the Indian App Store identifies the Indian patient-support platform, prescribed approved-use requirement and absence of full reimbursement. App reviews are not used as evidence; medicine-specific assistance terms are not published here.
- AZCares. Medicine-specific Indian portals: Tagrisso, Imfinzi and Enhertu.
Public login pages identify separate medicine routes within AZCares and AstraZeneca India. Medicine identities are cross-checked against AstraZeneca Pharma India’s annual report 2024–25. These pages establish access routes, not current assistance amounts or individual eligibility. No login or patient records accessed. Checked on 18 October 2026.
- Servier India. Patient Care and Support: Servier CARE.
Official Indian programme description, cross-checked with the 11 November 2025 programme announcement, which describes financial, medicine and diagnostic support for eligible patients. No per-drug support ratio is stated here.
- Servier India. Our Products: oncology medicines.
Indian product list includes Onivyde, Tibsovo and Voranigo. Generic identities cross-checked with the official Tibsovo announcement of 5 June 2025 and Voranigo announcement of 10 December 2025. Product listing is not evidence that every medicine is included in assistance.
- GSK India. Jemperli, Zejula and Phoenix announcement, 25 August 2025.
Primary confirmation of the Indian Phoenix patient-support programme associated with dostarlimab and niraparib. Official Indian contact route. Current financial terms and enrolment must be confirmed; promotional clinical claims are not reproduced.
- Lilly India. About Lilly: Indian patient enquiries.
Official Indian enquiry number, with company contacts. Abemaciclib and ramucirumab are included as medicine-specific enquiries requested for this directory, not as verified current Indian financial-assistance offers. Lilly’s medicine information corroborates drug identities only; no US assistance rules are applied to India.
- Niva Bupa. Health Premia policy wording, UIN MAXHLIP21176V022021.
Illustrative policy wording: second-opinion arrangements (section 3.21), overseas conditions and unproven-treatment exclusions. Not a product recommendation or confirmation of the reader’s cover.
- HDFC ERGO. Global plans under my:Optima Secure.
Primary insurer comparison distinguishing emergency-only and planned overseas treatment, payment arrangements, limits and optional travel support. Individual policy wording governs.
- National Cancer Institute. Who Pays for Clinical Trials? Updated 7 November 2024.
Used for the distinction between research costs and usual-care costs, and questions to ask. US insurance entitlements are not applied to India.
- National Cancer Institute. Clinical Trials: What to Expect.
Trial screening, consent, variable support and planning beyond participation; not evidence of Indian insurance coverage.
- Astellas. Global directory: Astellas Pharma India Private Limited.
Official Indian company contact. The number is regrouped in standard Indian telephone format without changing its digits. This source does not confirm any medicine-specific Indian financial-assistance entitlement.
- Directorate General of Health Services. Central Drugs Standard Control Organisation.
Official explanation of CDSCO’s role and leadership by the Drugs Controller General (India). Checked on 18 October 2026.
- US Food and Drug Administration. Frequently Asked Questions About Drugs.
Approval in another country does not itself establish FDA approval. Checked on 18 October 2026.
- European Medicines Agency. Obtaining an EU marketing authorisation, step by step.
Explains EMA assessment and European Commission authorisation through the centralised procedure. Checked on 18 October 2026.
Editorially approved by Dr (Prof) Vijay Agarwal
Professor and Lead Consultant – Medical Oncology
